title: Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features.
abstract: Mucinous breast cancer (MBC) is mainly a disease of postmenopausal women. Pure MBC is rare and augurs a good prognosis. In contrast, MBC mixed with other histological subtypes of invasive disease loses the more favorable prognosis. Because of the relative rarity of pure MBC, little is known about its cell and tumor biology and relationship to invasive disease of other subtypes. We have now developed a human breast cancer cell line called BCK4, in which we can control the behavior of MBC. BCK4 cells were derived from a patient whose poorly differentiated primary tumor was treated with chemotherapy, radiation and tamoxifen. Malignant cells from a recurrent pleural effusion were xenografted in mammary glands of a nude mouse. Cells from the solid tumor xenograft were propagated in culture to generate the BCK4 cell line. Multiple marker and chromosome analyses demonstrate that BCK4 cells are human, near diploid and luminal, expressing functional estrogen, androgen, and progesterone receptors. When xenografted back into immunocompromised cycling mice, BCK4 cells grow into small pure MBC. However, if mice are supplemented with continuous estradiol, tumors switch to invasive lobular carcinoma (ILC) with mucinous features (mixed MBC), and growth is markedly accelerated. Tamoxifen prevents the expansion of this more invasive component. The unexpected ability of estrogens to convert pure MBC into mixed MBC with ILC may explain the rarity of the pure disease in premenopausal women. These studies show that MBC can be derived from lobular precursors and that BCK4 cells are new, unique models to study the phenotypic plasticity, hormonal regulation, optimal therapeutic interventions, and metastatic patterns of MBC.
authors.affiliation: Division of Endocrinology, Department of Medicine, University of Colorado, Anschutz Medical Campus, Mail Stop 8106, Aurora, CO 80045, USA.
authors.forename: Purevsuren
authors.initials: P
authors.lastname: Jambal
authors.forename: Melanie M
authors.initials: MM
authors.lastname: Badtke
authors.forename: J Chuck
authors.initials: JC
authors.lastname: Harrell
authors.forename: Virginia F
authors.initials: VF
authors.lastname: Borges
authors.forename: Miriam D
authors.initials: MD
authors.lastname: Post
authors.forename: Grace E
authors.initials: GE
authors.lastname: Sollender
authors.forename: Monique A
authors.initials: MA
authors.lastname: Spillman
authors.forename: Kathryn B
authors.initials: KB
authors.lastname: Horwitz
authors.forename: Britta M
authors.initials: BM
authors.lastname: Jacobsen
mesh_terms: D000368:Aged; D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D018275:Carcinoma, Lobular / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004958:Estradiol / Q000494:pharmacology; D004967:Estrogens / Q000378:metabolism*; D005260:Female; D006801:Humans; D007621:Karyotyping; D051379:Mice; D008819:Mice, Nude; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D013629:Tamoxifen / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays
chemical_list: D004967:Estrogens; D013629:Tamoxifen; D004958:Estradiol